Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

BMS-986205

Phase 3Biologic

Bristol-Myers Squibb

BMS-986205 is an experimental drug being studied to treat certain types of cancer and immune system disorders by blocking a protein called IKAROS degradation[1] BMS-986205 is currently being investigated across 12 indications[3], with its most advanced program in Phase 3.[1]

BMS-986205 is one of 334 biologic programs targeting Pancreatic Carcinoma. It is currently in Phase 3.

12

Indications

20

Total Trials

1

Active Trials

333

Competitors

Pipeline

Status by Indication[3][1]

Indication

Pancreatic CarcinomaActive, not recruiting

Esophageal CarcinomaActive, not recruiting

Ovarian CarcinomaActive, not recruiting

Liver CancerActive, not recruiting

Non-Small Cell Lung CancerActive, not recruiting

MelanomaActive, not recruiting

Bladder CancerActive, not recruiting

Renal Cell CarcinomaActive, not recruiting

Gastric CancerActive, not recruiting

Endometrial CancerActive, not recruiting

Pancreatic CarcinomaPhase 3

Active, not recruiting

Esophageal CarcinomaPhase 2

Active, not recruiting

Ovarian CarcinomaPhase 2

Active, not recruiting

Liver CancerPhase 3

Active, not recruiting

Non-Small Cell Lung CancerPhase 2

Active, not recruiting

MelanomaPhase 2

Active, not recruiting

Bladder CancerPhase 2

Active, not recruiting

Renal Cell CarcinomaPhase 2

Active, not recruiting

Gastric CancerPhase 2

Active, not recruiting

Endometrial CancerPhase 2

Active, not recruiting

Showing 10 of 12 indications

Competition

Competitive Landscape

1639 competitors in Non-Small Cell Lung Cancer

#DrugCompanyPhaseTrials

BMS-986205

Bristol-Myers Squibb

Gemzar

GGynecologic Oncology Group

PORTRAZZA

Lenvima

Imjudo

Vizimpro

Gilotrif

Boehringer Ingelheim

Tyrosine Kinase Inhibitor

Vibramycin

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Treatment

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2026

Phase 2Active, not recruiting

Endometrial Cancer

NCT04106414

Clinical

Trials by Indication[1]

Absorption2 trials

A Study in Healthy Participants Evaluating the Absorption of a BMS-986205 Tablet Into the Bloodstream Compared to a Reference Tablet

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 1·NCT03378310·16 enrolled

An Investigational Study to Assess the Effect of a Light Meal and a High-Fat Meal on the Absorption of BMS-986205 in Healthy Participants

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 1·NCT03312426·32 enrolled

Nivolumab2 trials

An Investigational Immuno-therapy Study of BMS-986205 Given in Combination With Nivolumab and in Combination With Both Nivolumab and Ipilimumab in Cancers That Are Advanced or Have Spread

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 1/2·NCT02658890·627 enrolled

A Study of BMS-986205 Given in Combination With Nivolumab in Patients With Advanced Tumors

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 1·NCT03192943·11 enrolled

Non-Small Cell Lung Cancer2 trials

An Investigational Immuno-therapy Study to Test Combination Treatments in Patients With Advanced Non-Small Cell Lung Cancer

Terminated· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 2·NCT02750514·295 enrolled

An Immuno-Therapy Study of Experimental Medication BMS-986205 Given With Nivolumab With or Without Chemotherapy Compared to Chemotherapy in Participants With Previously Untreated Stage IV or Recurrent Non-Small Cell Lung Cancer

Withdrawn· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 3·NCT03417037

Tics2 trials

A Study to Evaluate the Effect of Omeprazole on the Pharmacokinetics of BMS-986205 in Healthy Participants

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 1·NCT03936374·16 enrolled

A Study to Evaluate the Effect of 2 Drugs on the Pharmacokinetics of BMS-986205 in Healthy Subjects

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 1·NCT03346837·53 enrolled

Melanoma2 trials

An Investigational Immuno-therapy Study of BMS-986205 Combined With Nivolumab, Compared to Nivolumab by Itself, in Patients With Advanced Melanoma

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 3·NCT03329846·20 enrolled

A Phase II Trial of Neoadjuvant Treatment With PD-1 Inhibition (Nivolumab) With or Without IDO Inhibition (BMS-986205) and With or Without CTLA-4 Inhibition (Ipilimumab) in Resectable Stage III or IV Melanoma

Withdrawn·—·Phase 2·NCT04007588

10 more indications

Gastric Cancer1 trial

A Study to Test Combination Treatments in Participants With Advanced Gastric Cancer

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 2·NCT02935634·190 enrolled

Single Dose1 trial

A Study to Assess the Absorption of a Single Dose of BMS-986205 in Healthy Volunteers When Administered as a Crushed Tablet Orally or Crushed Tablet Suspension Via Nasogastric Tube, as Compared to a Tablet

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 1·NCT03362411·40 enrolled

Renal Cell Carcinoma1 trial

A Study to Test Combination Treatments in People With Advanced Renal Cell Carcinoma

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 2·NCT02996110·182 enrolled

Bladder Cancer1 trial

A Study of Nivolumab or Nivolumab Plus Experimental Medication BMS-986205 With or Without Bacillus Calumette-Guerin (BCG) in BCG Unresponsive Bladder Cancer That Has Not Invaded Into the Muscle Wall of the Bladder

Terminated· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 2·NCT03519256·142 enrolled

Squamous Cell Carcinoma1 trial

An Immuno-therapy Study of Nivolumab in Combination With Experimental Medication BMS-986205 Compared to Standard of Care EXTREME Regimen in First-line Recurrent/Metastatic Squamous Cell Carcinoma of Head and Neck

Withdrawn· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 3·NCT03386838

Immunotherapy1 trial

An Investigational Study of Immunotherapy Combinations in Participants With Solid Cancers That Are Advanced or Have Spread

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 1/2·NCT03459222·229 enrolled

Endometrial Cancer1 trial

Study of BMS-986205 and Nivolumab in Endometrial Cancer or Endometrial Carcinosarcoma That Has Not Responded to Treatment

Active, not recruiting·MMemorial Sloan Kettering Cancer Center·Phase 2·NCT04106414·24 enrolled

Advanced Malignant Solid Tumors1 trial

A Study of BMS-986205 Alone and in Combination With Nivolumab in Chinese Patients With Advanced Malignant Solid Tumors

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 1/2·NCT03792750·12 enrolled

Metabolism1 trial

Pharmacokinetics and Metabolism Study in Healthy Male Participants

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 1·NCT03247283·9 enrolled

Unspecified1 trial

A Study to Evaluate the Bioavailability of BMS-986205

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 1·NCT03374228·7 enrolled

Sources

References

[1]
ClinicalTrials.gov — 20 trial records for BMS-986205. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — BMS-986205 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for BMS-986205. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Bristol-Myers Squibb company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Phase 3[1]
Company: Bristol-Myers Squibb

Related News